

By: Representatives Hines, Nelson

To: Insurance

COMMITTEE SUBSTITUTE
FOR
HOUSE BILL NO. 1527

1 AN ACT TO PROHIBIT HEALTH BENEFIT PLANS, PHARMACY BENEFIT
2 MANAGERS AND PRIVATE REVIEW AGENTS FROM SUBJECTING DRUGS
3 PRESCRIBED FOR THE TREATMENT OR PREVENTION OF HIV OR AIDS TO A
4 PRIOR AUTHORIZATION REQUIREMENT, STEP THERAPY, OR ANY OTHER
5 PROTOCOL THAT COULD RESTRICT OR DELAY THE DISPENSING OF THE DRUG;
6 AND FOR RELATED PURPOSES.

7 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

8 **SECTION 1.** (1) As used in this section, the following terms
9 shall be defined as provided in this subsection:

10 (a) "Health benefit plan" means services consisting of
11 medical care, provided directly, through insurance or
12 reimbursement, or otherwise, and including items and services paid
13 for as medical care under any hospital or medical service policy
14 or certificate, hospital or medical service plan contract,
15 preferred provider organization, or health maintenance
16 organization contract offered by a health insurance issuer. The
17 term "health benefit plan" includes the Medicaid fee-for-service
18 program and any managed care program, coordinated care program,
19 coordinated care organization program, health maintenance



20 organization program or such other programs implemented by the
21 Division of Medicaid under Section 43-13-117(H).

22 (b) "Pharmacy benefit manager" has the meaning as
23 defined in Section 73-21-179.

24 (c) "Private review agent" has the meaning as defined
25 in Section 41-83-1.

26 (2) A health benefit plan, pharmacy benefit manager or
27 private review agent shall not restrict access to antiretroviral
28 drugs including, but not limited to, long-acting injectable
29 FDA-approved antiretroviral drugs prescribed for the treatment or
30 prevention of the human immunodeficiency virus (HIV) or acquired
31 immunodeficiency syndrome (AIDS), on the basis of being "not
32 medically necessary," and shall include at least one (1)
33 long-acting injectable antiretroviral medication in its formulary
34 that may or may not require prior authorization.

35 **SECTION 2.** This act shall take effect and be in force from
36 and after July 1, 2024.

